ACADIA Pharmaceuticals Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Unaudited consolidated interim results. ACADIA is a clinical-stage biopharmaceutical company; it had no product sales and relied primarily on collaboration and grant revenue.
Financial highlights
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $0.599 million | $0.460 million | $1.049 million | $0.895 million |
| Research and development expense | $4.472 million | $4.315 million | $9.493 million | $8.727 million |
| General and administrative expense | $1.556 million | $2.729 million | $3.216 million | $4.613 million |
| Net loss | $5.419 million | $6.556 million | $11.637 million | $12.389 million |
| Net loss per share | $0.10 | $0.12 | $0.22 | $0.24 |
| Operating cash used | Not separately reported | Not separately reported | $10.030 million | $10.387 million |
- At June 30, cash and cash equivalents were $9.208 million and available-for-sale investments were $12.141 million, totaling $21.349 million, versus $31.048 million at December 31, 2011.
- Six-month investing cash flow was positive $12.270 million, mainly reflecting investment maturities exceeding purchases. Financing cash flow was positive $0.079 million; the prior-year period included $13.9 million of private-placement proceeds.
- Total liabilities were $9.166 million, including $13,000 current debt and $3.171 million deferred revenue. The filing reports no material long-term debt balance. No operating margin is presented; the company remained loss-making.
- Accumulated deficit was $358.5 million. Basic and diluted weighted-average shares were 52.961 million in Q2 and 52.932 million for the first half of 2012.
Changes versus comparable periods
- Q2 revenue rose 30% year over year, mainly from higher research-grant revenue. First-half revenue increased 17%.
- R&D expense increased 4% in Q2 and 9% for the first half, primarily because of higher external clinical costs for the Phase III pimavanserin program. First-half external R&D costs rose to $7.1 million from $5.7 million.
- G&A expense declined substantially: the 2011 comparison included a $1.1 million net charge related to termination of the Swedish facility lease; 2012 also had lower personnel and other administrative costs.
- Net losses narrowed in both comparisons, reflecting lower G&A expense, partly offset by higher R&D spending.
Outlook, commentary and risks
- Management expected existing cash, cash equivalents and investments, together with anticipated collaboration payments, to fund operations at least into the second quarter of 2013. Significant additional financing will be needed; availability and terms are uncertain.
- ACADIA expected continued operating losses for at least several years and could need to delay, reduce or discontinue programs, or license rights on less favorable terms, if it cannot raise capital.
- The lead program, pimavanserin, was in Phase III development for Parkinson’s disease psychosis. Management expected top-line results from the pivotal -020 study in fall 2012. The filing highlights prior unsuccessful Phase III results and the risk of another unfavorable outcome.
- In July 2012, after quarter-end, ACADIA and Meiji Seika Pharma discontinued AM-831 development and terminated their collaboration. ACADIA expected to recognize the remaining $2.8 million of deferred revenue in Q3 2012 after its performance obligations ended.
- Three Allergan collaborations remained in place. The 2003 research term had been extended through March 2013; milestone payments and future royalties depended on development progress and, for royalties, future product sales. The filing also notes Allergan was seeking a partner for the chronic-pain program.
- The company had an ATM facility allowing up to $20 million of stock sales over three years; no shares had been sold under it by June 30, 2012. Potential dilution and dependence on capital markets are risks.
- Contracted future services with research organizations and other providers were up to approximately $5.4 million, generally stoppable on short notice. Operating leases and debt totaled $0.392 million in the contractual-obligations table. Potential Ipsen milestone payments of up to $10.5 million were contingent and excluded from that table.
- Investment securities were rated at least AA or A1+/P1; management stated a 10% interest-rate change would not materially affect portfolio fair value. Disclosure controls were assessed as effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting identified.
Investor verification priorities
- Check the eventual -020 Phase III results and subsequent regulatory and development updates for pimavanserin.
- Verify cash runway against actual spending, collaboration receipts and subsequent financing; assess the terms and dilution from any ATM or other equity issuance.
- Confirm Q3 recognition of the $2.8 million Meiji deferred revenue and evaluate the effect of losing the AM-831 collaboration.
- Monitor the Allergan research-term extension, chronic-pain partnering and progress toward collaboration milestones.
- Review changes in clinical-trial costs, accrued clinical and research services, and the company’s ability to fund development without product-sales revenue.